BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260224T110000
DTEND;TZID=America/New_York:20260224T123000
DTSTAMP:20260403T191509
CREATED:20251217T142722Z
LAST-MODIFIED:20260126T190806Z
UID:2858-1771930800-1771936200@lifescievents.com
SUMMARY:Tectonic Therapeutic Virtual KOL Event and TX2100 Deep Dive: A Novel Program for the Treatment of Hereditary Hemorrhagic Telangiectasia
DESCRIPTION:Please join Tectonic Therapeutic for a virtual key opinion leader (KOL) event featuring Hanny Al-Samkari\, MD (Massachusetts General Hospital\, Harvard Medical School)\, who will join company management to discuss the TX2100 program. The management team will review the target\, mechanistic rationale and preclinical evidence supporting its GPCR antagonist strategy\, and Dr. Al-Samkari will provide clinical context on Hereditary Hemorrhagic Telangiectasia (HHT)\, including disease burden\, unmet medical need\, and limitations of current treatment approaches. \nThe event will highlight Tectonic’s TX2100\, a GPCR antagonist targeting a pathway that\, together with its ligand\, has been described to play a role in the formation of arteriovenous malformations (AVMs) and pathological angiogenesis. TX2100 is a potential first-in-class therapeutic candidate for the treatment of HHT\, the second most common inherited bleeding disorder. Tectonic plans to initiate a Phase 1 clinical trial in 1Q 2026. \nFormal presentations will be followed by a live question and answer session with Dr. Al-Samkari and company management. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/pl305f8/.
URL:https://lifescievents.com/event/pl305f8/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2025/12/Tectonic-Banner.png
END:VEVENT
END:VCALENDAR